Farnesyltransferase inhibitors: Novel compounds in development for the treatment of myeloid malignancies

Seminars in Hematology

Volumn 39, Issue 3 SUPPL. 2, 2002, Pages 26-30

  Cortes, Jorge E ^a   Kurzrock, Razelle ^a   Kantarjian, Hagop M ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 BENZYL 7 CYANO 2,3,4,5 TETRAHYDRO 1 (1H IMIDAZOL 4 YLMETHYL) 4 (2 THIENYLSULFONYL) 1H 1,4 BENZODIAZEPINE; 5 [N [5 (2 BENZOXAZOLYL) 1 METHYL 2 [3,4 (METHYLENEDIOXY)PHENYL] 4 PENTENYL] N (2 NAPHTHYLMETHYL)CARBAMOYL] 1,3 DIOXOLANE 2,2,4 TRICARBOXYLIC ACID; L 731735; L 778123; LONAFARNIB; N (8 AMINO 2 BENZYL 5 ISOPROPYL 9 MERCAPTO 3,6 NONADIENOYL)METHIONINE; N [[5 [(2 AMINO 3 MERCAPTOPROPYL)AMINO][1,1' BIPHENYL] 2 YL]CARBONYL]METHIONINE; PROTEIN FARNESYLTRANSFERASE INHIBITOR; RPR 115135; TIPIFARNIB; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; ENZYME INHIBITOR; FARNESYL TRANS TRANSFERASE; TRANSFERASE;

ANGIOGENESIS; APOPTOSIS; ARTICLE; BONE MARROW SUPPRESSION; CARDIOTOXICITY; CELL PROLIFERATION; CLINICAL TRIAL; CONFUSION; DIARRHEA; DRUG ACTIVITY; DRUG MECHANISM; ENZYME INHIBITION; FATIGUE; FEVER; HEADACHE; HUMAN; MYELODYSPLASTIC SYNDROME; MYELOID LEUKEMIA; NEPHROTOXICITY; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; QT INTERVAL; CHEMISTRY; CLASSIFICATION; DRUG ANTAGONISM; REVIEW; STRUCTURE ACTIVITY RELATION;

ALKYL AND ARYL TRANSFERASES; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; ENZYME INHIBITORS; FARNESYLTRANSTRANSFERASE; HUMANS; MYELODYSPLASTIC SYNDROMES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0036655361     PISSN: 00371963     EISSN: None     Source Type: Journal    
DOI: 10.1053/shem.2002.35984     Document Type: Article

References (33)

1. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia
2. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse
3. Non-Ras targets of farnesyltransferase inhibitors: Focus on Rho
4. Farnesyltransferase inhibitors define a role for RhoB in controlling neoplastic pathophysiology
5. Ras protein farnesyl-transferase: A strategic target for anticancer therapeutic development
6. Farnesyl transferase inhibitors block the farnesylation of CENP-E and CENP-F and alter the association of CENP-E with the microtubules
7. RhoB, not RhoA, represses the transcription of the transforming growth factor beta type II receptor by a mechanism involving activator protein 1
8. Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R 115777 in vivo and in vitro
9. The prenylation of proteins
10. Polylysine and CVIM sequences of K-RasB dictate specificity of prenylation and confer resistance to benzodiazepine peptidomimetic in vitro
11. Manumycin and gliotoxin derivative KT 7595 block Ras farnesylation and cell growth but do not disturb lamin farnesylation and localization in human tumour cells
12. RPR-115135, a new non peptidomimetic farnesyltransferase inhibitor, induces G0/G 1 arrest only in serum starved cells
13. J-104,871, a novel farnesyltransferase inhibitor, blocks Ras farnesylation in vivo in a farnesyl pyrophosphate-competitive manner
14. Early clinical experience with farnesyl protein transferase inhibitors: From the bench to the bedside
15. A phase I and pharmacological study of the farnesyl protein transferase inhibitor L-778,123 in patients with solid malignancies
16. A phase I and PK study of farnesyl transferase inhibitor L-778,123 administered as a seven day continuous infusion in combination with paclitaxel
17. Bisubstrate inhibitors of farnesyltransferase: A novel class of specific inhibitors of ras transformed cells
18. Effects of farnesyl transferase inhibitor R115777 on hematopoiesis, leukemic cell proliferation, and signaling through the mitogen-activated protein kinase (MAPK) pathway
19. Antitumor activity of SCH 66336, an orally bioavailable tricyclic inhibitor of farnesyl protein transferase, in human tumor xenograft models and wap-ras transgenic mice
20. Treatment of Bcr/Abl-positive acute lymphoblastic leukemia in P 190 transgenic mice with the farnesyl transferase inhibitor SCH66336
21. Activity of the farnesyl protein transferase inhibitor SCH66336 against BCR/ABL-induced murine leukemia and primary cells from patients with chronic myeloid leukemia
22. Combined cell cycle and cytotoxic effects of paclitaxel and R115777, a specific inhibitor of p21 ras function and protein farnesylation in human prostate and breast carcinoma cell lines
23. Preclinical antitumor activity of BMS-214662, a highly apoptotic and novel farnesyltransferase inhibitor
24. Dose escalation study of oral farnesyl transferase inhibitor (FTI) BMS-214662 in patients with solid tumors
25. Pharmacokinetics (PK) and pharmacodynamics (PD) of the farnesyltransferase (FT) inhibitor BMS-214662 in patients with advanced solid tumors
26. Phase I study of farnesyl transferase inhibitor, BMS-214662 in solid tumors
27. A phase I study of the farnesyltransferase (FT) inhibitor BMS-214662 administered as a weekly 1-hour infusion in patients (Pts) with advanced solid tumors: Clinical findings
28. Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: A phase 1 clinical-laboratory correlative trial
29. Interim results from a phase II study of R115777 (ZARNESTRA) in patients with relapsed and refractory acute myelogenous leukemia
30. R115777, a farnesyl transferase inhibitor (FTI), has significant anti-leukemia activity in patients with chronic myeloid leukemia (CML)
31. Phase II study of R115777, a farnesyltransferase inhibitor, in myelodysplastic syndrome
32. Phase I study of a farnesyl transferase inhibitor, R115777, in patients with myelodysplastic syndrome
33. Phase I study of a farnesyl transferase inhibitor (FTI), BMS-214662, in patients with refactory or relapsed acute leukemias